HONGKONG DOCAN TECHNOLOGY CO., LIMITED – Trademark Portfolio
Entity Type: 99
HONGKONG DOCAN TECHNOLOGY CO., LIMITED holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 3 filings in this category. The portfolio also extends into Class 34 (Smokers Articles) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include APEXIUM and SAFECEL. The owner is based in CENTRAL.
RM 1302 13/F CHEONG K BUILDING
84-86 DES VOEUX ROAD
CENTRAL 999077 , HK
Showing of trademarks Trademarks
Trademark Classifications
HONGKONG DOCAN TECHNOLOGY CO., LIMITED's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does HONGKONG DOCAN TECHNOLOGY CO., LIMITED have?
HONGKONG DOCAN TECHNOLOGY CO., LIMITED has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.
What trademark classes does HONGKONG DOCAN TECHNOLOGY CO., LIMITED file in?
HONGKONG DOCAN TECHNOLOGY CO., LIMITED files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 34 (Smokers Articles). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are HONGKONG DOCAN TECHNOLOGY CO., LIMITED's most well-known trademarks?
HONGKONG DOCAN TECHNOLOGY CO., LIMITED's registered trademark portfolio includes well-known marks such as APEXIUM and SAFECEL. These are among 3 currently registered trademarks in the portfolio.
What is HONGKONG DOCAN TECHNOLOGY CO., LIMITED's trademark registration success rate?
HONGKONG DOCAN TECHNOLOGY CO., LIMITED has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.